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Abstract
Background: Inositol-1,4,5-trisphosphate-3-kinase-A (ITPKA) has recently been found to be implicated in the tumor
progression of various cancers. However, the expression and the prognostic value of ITPKA in hepatocellular
carcinoma (HCC) remains unexplored. The aim of this study is to investigate the clinical significance of ITPKA
expression in HCC.
Methods: We determined the expression level of ITPKA in 135 cases of HCC tissues and the matched adjacent
nontumorous tissues by quantitative real-time RT-PCR. The correlation between ITPKA expression and prognosis of
HCC patients was further evaluated by univariate and multivariate analysis. Multivariate analysis of the prognostic
factors was performed with Cox proportional hazards model.
Results: Up-regulation of ITPKA occurred in 48.9 % of primary HCCs compared with their nontumor counterparts
(P < 0.001). In addition, high expression of ITPKA was significantly associated with vascular invasion (P = 0.001) and
TNM stage (P = 0.005). Kaplan–Meier analysis showed that the 5-year overall survival (OS) and relapse-free survival
(RFS) rate in the group with high expression of ITPKA is poorer than that in low expression group (32.2 and 26.8 %
versus 59.2 and 57.7 %). Univariate and multivariate analyses revealed that ITPKA was an independent prognostic
factor for OS and RFS. Moreover, Stratified analysis revealed that its prognostic significance still existed within the
subgroup of patients with early clinical stage (TNM stage I) or normal serum AFP level (≤25 μg/L).
Conclusion: Our data indicated that ITPKA expression was significantly up-regulated in HCC and could serve as a
potential novel prognostic biomarker for HCC patients after surgery.
Background
Hepatocellular carcinoma (HCC) is a highly lethal can-
cer, which has been ranked as the fifth most common
malignancy and the third leading cause of cancer-related
mortality worldwide [1–4]. Despite of the tremendous
progress in diagnosis and multimodality treatment in the
past decades, the prognosis of HCC patients remains
grim, mainly because of its high recurrent and meta-
static rate [5]. To date, numerous studies have identified
a mass of dysregulated molecular events involved in liver
carcinogenesis, which cover a wide range of genes with
various functions. However, the biomarkers for HCC
remain unsatisfactory in terms of high-risk population
screening, clinical diagnosis and prognosis, and evalu-
ation of treatment efficiency. Therefore, it is imperative
to identify and characterize novel biomarkers for this
disease.
With the advent of high-throughput sequencing tech-
nologies in recent years, transcriptome sequencing
(RNA-Seq) has been a powerful tool for gene expression
profiling in the study of cancer. Recently, our group
exploited a RNA-Seq to delineate differential gene ex-
pression in ten pairs of HCC and nontumor clinical
samples. Overexpression of inositol-1,4,5-trisphosphate-
3-kinase-A (ITPKA) was observed in all ten HCC tumor
tissues compared with their matched nontumoral coun-
terparts. ITPKA gene, which is located in 15q15, encodes
a predicted 461 amino acid polypeptide. Under physio-
logical conditions, ITPKA is only identified in neurons
and testis [6]. It is one of the three inositol trisphosphate
3-kinases (ITPKs) isoforms (A, B and C) that catalyse
the phosphorylation of the second messenger inositol
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1,4,5-trisphosphate (Ins(1, 4, 5)P3) to inositol 1, 3, 4, 5-
tetrakisphosphate (Ins(1, 3, 4, 5)P4), and thus regulate
Ins(1, 4, 5)P3-induced calcium (Ca
2+) signals [7, 8]. Inde-
pendent of this catalytic activity, ITPKA also binds and
bundles filamentous actin (F-actin) to regulate the spine
morphology [9]. Beside these physiological roles, ITPKA
plays an important role in the carcinogenesis and metas-
tasis. Down-regulated ITPKA expression was identified
in oral squamous cell carcinoma (OSCC) tissues and
OSCC cell lines [10]. Whereas in contrast, recent studies
on lung cancer showed that high expression of ITPKA
was detected in primary tumors and the matched lymph
node metastases [11]. Furthermore, the analysis of RNA-
seq data for kidney renal clear cell carcinoma patients
showed that up-regulated ITPKA expression was associ-
ated with advanced stage and lower survival rates [12].
Taken together, we hypothesize that ITPKA may be a
useful metastasis and prognostic marker for HCC.
In the present study, we investigated the expression
levels of ITPKA in HCC and their paired adjacent non-
tumorous tissues, and further evaluated the correlation
of ITPKA expression with clinical parameters and its
prognostic value in HCC.
Methods
Patients and tissue samples
One hundred thirty five paired primary HCC tumor
and nontumorous tissue samples were collected im-
mediately after surgery resection at Sun Yat-sen
University Cancer Center between December 2003 and
September 2009. The enrollment criteria were as follows:
(a) definitive HCC diagnosis by pathology based on WHO
criteria; (b) no preoperative trans-hepatic arterial chemo-
embolization or chemotherapy or radiotherapy before
surgery; (c) surgical resection, defined as complete re-
section of all tumor nodules with the cut surface being
free of cancer by histologic examination; (d) complete
clinicopathologic and follow-up data. Ethical approval for
this study was granted by the Medical Ethics Committee
of Sun Yat-sen University Cancer Center. All patients
signed informed consent. In this study, nontumoral liver
tissues were defined as 2.0 cm from the tumor margin,
which had been described previously [13]. Hepatitis B
history was defined as history with positive serum
hepatitis B surface antigen (HBsAg). Tumor encapsu-
lation was defined as the presence of a clear fibrous
sheath around the tumor at gross inspection. Tumor
differentiation was based on the Edmondson and
Steiner classification. HCC metastasis was defined as
the presence of vascular invasion in the portal vein or
the presence of satellite nodules surrounding a larger
main tumor [14]. Tumor staging was determined ac-
cording to the 7th edition tumor-node-metastasis
(TNM) classification of the American Joint Committee
on Cancer.
Cell lines and culture conditions
HCC cell lines BEL7402, Hep3B, PLC8024, QSG7701,
QGY7703, SMMC7721 and immortalized liver cell line
LO2 were obtained from the Institute of Virology,
Chinese Academy of Medical Sciences (Beijing, China).
Huh7 was purchased from American type culture col-
lection (ATCC, Manassas, Virginia, USA). Cells were
maintained in high-glucose DMEM (Gibco BRL, Grand
Island, NY) supplemented with 10 % fetal bovine serum
(FBS) (Gibco BRL, Grand Island, NY). The cells were
incubated at 37 °C in a humidified incubator containing
5 % CO2.
Quantitative real-time reverse transcription polymerase
chain reaction (qRT-PCR)
All fresh tumorous and nontumorous tissue samples
were immediately stored at dry ice after resection and
then frozen at −80 °C. Total RNA was extracted from
clinical samples or cell lines using TRIzol reagent (Invi-
trogen), and was reverse-transcribed using an Advantage
RT-for-PCR Kit (Clontech Laboratories) according to
the manufacturer’s instructions. qRT-PCR was performed
to detect levels of the corresponding glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and ITPKA using a
SYBR Green PCR Kit (Applied Biosystems) and Light-
Cycler480 384-well PCR system (Roche Diagnostics).
The GAPDH was used as an internal control for
ITPKA. Primers for ITPKA are 5’-CCTTTCCACCTC
GTCGGTCT-3’ (forward) and 5’-GCCTTAAAACT
CCCAGTGTGC-3’ (reverse). Primers for GAPDH are
5’-ACTTCAACAGCGACACCCACTC-3’ (forward) and
5’-TACCAGGAAATGAGCTTGACAAAG-3’ (reverse). The
value of relative expression for each sample was averaged
and compared using the Ct method. ΔΔCt(sample) =
ΔCt(sample) - ΔCt(calibrator), ΔCt(sample) =Ct(sample) of
ITPKA - Ct(sample) of GAPDH; ΔCt(calibrator) =Ct(calibrator)
of ITPKA - Ct(calibrator) of GAPDH; calibrator was
defined as the pooled samples from 135 adjacent non-
tumorous tissues.
Western blot analysis
ITPKA protein expression in cell lines was detected by
Western blotting. Briefly, cells were washed twice with
ice-cold PBS. Total protein was extracted with lysis
buffer for 45 min on ice. Equal amounts of protein
were separated by 12 % SDS-PAGE and electrophoret-
ically transferred to polyvinylidene difluoride mem-
branes (Millipore) using a mini trans-blot apparatus
(Bio-Rad Laboratories). Membranes were blocked with
PBS-0.05 % Tween 20 containing 5 % nonfat dry milk
for one hour at room temperature and incubated with
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polyclonal rabbit anti-ITPKA (1:1,000; Proteintech) or
monoclonal mouse anti-GAPDH antibody (1:5,000;
Vazyme Biotech) at 4 °C overnight. Membranes were
then washed three times with PBS-0.05 % Tween 20
and incubated with horseradish peroxidase–conjugated
goat anti-rabbit or anti-mouse IgG (Santa Cruz Bio-
technology) at a 1:5,000 dilution for one hour at room
temperature. Blots were developed using an enhanced
chemiluminescence kit (Pierce). Each experiment was
repeated at least three times.
Fig. 1 ITPKA was up-regulated in HCCs. a ITPKA mRNA was markedly increased in tumor tissues than that in the paired adjacent nontumor tissues.
**, P < 0.001, paired t-test. b Up-regulation of ITPKA was detected in 4 of 7 HCC cell lines by qRT-PCR (upper) and western blot analysis (lower).
Immortalized liver cell line (LO2) was used as control
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Statistical analysis
All statistical analyses were performed using the Statis-
tical Package for the Social Sciences (SPSS) version 16.0
(SPSS Inc, Chicago, IL). Paired two-tailed student’s t test
was used to compare the expression of ITPKA in pri-
mary HCC tumors and their corresponding adjacent
nontumorous tissues. The correlation between ITPKA ex-
pression and clinicopathological parameters was assessed
by chi-square test or Fisher’s exact test. Disease-specific
survival was calculated from the time of surgery to
either the time of death from HCC or last follow up
(31 December 2014). The prognostic value was calcu-
lated by the Kaplan-Meier analysis with log-rank test.
Univariate and multivariate survival analysis was
performed using the Cox proportional hazard model
with a forward stepwise procedure (the entry and
removal probabilities were 0.05 and 0.10, respectively).
A significant difference was considered statistically
when P value was <0.05.
Results
ITPKA expression was up-regulated in HCC
Our prior RNA-seq profiling data showed that ITPKA
was overexpressed in all ten tested HCC tumor tissues.
High expression of ITPKA (defined as > 2-fold change)
was detected in 66 of 135 (48.9 %) of HCC tissues by
qRT-PCR, compared with their normal counterparts.
The average level of ITPKA expression in tumor tissues
was significantly higher than that in non-tumor tissues
(1.11 versus 3.01, P < 0.001, paired Student’s t test;
Fig. 1a). The median fold change of ITPKA (1.84) in
HCC tumor tissues was used as a cutoff value to divide
all 135 patients into two groups: the high expression
group (n = 66) and the low expression group (n = 69).
The expression levels of ITPKA in seven HCC cell lines
and one immortalized liver cell line (LO2) were tested
by qRT-PCR and western blot analysis. Compared with
LO2, up-regulation of ITPKA was detected in QGY7703,
Hep3B, Huh7 and PLC8024 cells (Fig. 1b).
Clinicopathologic features of ITPKA in HCC patients
The correlation between ITPKA mRNA expression in
primary HCC and clinicopathological features was sum-
marized in Table 1. High expression of ITPKA was sig-
nificantly associated with vascular invasion (P = 0.001)
and TNM stage (P = 0.005). No correlation was observed
between ITPKA expression and other clinicopathological
characteristics.
Association between ITPKA expression and patient
survival
Univariate analysis showed that HBsAg, serum AFP level,
tumor size, tumor number, vascular invasion, TNM stage,
and ITPKA expression were prognostic factors for OS and
RFS (Table 2). The 5-year OS and RFS rate in the high
ITPKA expression group were significantly lower than
those in the low ITPKA expression group (32.2 and 26.8 %
versus 59.2 and 57.7 %; Fig. 2a). Considering that the
TNM stage was correlated with several clinical indexes
(such as tumor size, tumor number, and vascular inva-
sion), we did not introduce it into the multivariate Cox
proportional hazard model to avoid potential bias. The
Table 1 Association of ITPKA expression with clinicopathological
features in HCCs
Clinical features Cases ITPKA expression P
valuelow level (%) high level (%)
Age (years old) 0.945
≤50 63 32 (50.8 %) 31 (49.2 %)
>50 72 37 (51.4 %) 35 (48.6 %)
Gender 1.000
Male 128 65 (50.8 %) 63 (49.2 %)
Female 7 4 (57.1 %) 3 (42.9 %)
HBsAg 0.201
Negative 15 10 (66.7 %) 5 (33.3 %)
Positive 120 59 (49.2 %) 61 (50.8 %)
AFP (μg/L) 0.212
≤25 48 28 (58.3 %) 20 (41.7 %)
>25 87 41 (47.1 %) 46 (52.9 %)
Cirrhosis 0.569
No 23 13 (56.5 %) 10 (43.5 %)
Yes 112 56 (50.0 %) 56 (50.0 %)
Tumor size (cm) 0.126
≤5 56 33 (58.9 %) 23 (41.1 %)
>5 79 36 (45.6 %) 43 (54.4 %)
Tumor number 0.116
Solitary 104 57 (54.8 %) 47 (45.2 %)
Multiple 31 12 (38.7 %) 19 (61.3 %)
Tumor encapsulation 0.455
Complete 43 24 (55.8 %) 19 (44.2 %)
None 92 45 (48.9 %) 47 (51.1 %)
Vascular invasion 0.001
Absent 114 65 (57.0 %) 49 (43.0 %)
Present 21 4 (19.0 %) 17 (81.0 %)
Edmondson-Steiner 0.106
I-II 79 45 (57.0 %) 34 (43.0 %)
III-IV 56 24 (42.9 %) 32 (57.1 %)
TNM stage 0.005
I 93 55 (59.1 %) 38 (40.9 %)
II-III 42 14 (33.3 %) 28 (66.7 %)
Statistical significance (P < 0.05) is shown in bold
Li et al. Diagnostic Pathology  (2015) 10:136 Page 4 of 8
multvariate analysis demonstrated that ITPKA expression,
HBsAg and vascular invasion were independent prognos-
tic predictors for RFS (Table 3). Further, in a stratified
survival analysis according to the TNM stage or serum
AFP level, we found that the prognostic significance of
ITPKA was retained in TNM stage I (P = 0.001), nor-
mal AFP level (≤25 μg/L; P = 0.047) and high AFP
level (>25 μg/L; P = 0.001) subgroups (Fig. 2b and c).
Discussion and conclusions
The intracellular second messenger Ins(1,4,5)P3 controls
many different cellular functions by regulating internal
Ca2+ signals [7]. The lifetime of Ins(1,4,5)P3 is tightly
regulated by two mechanisms: phosphorylation via
ITPKs to Ins(1,3,4,5)P4 or dephosphorylation via
ins(1,4,5)P3 5-phosphatase (INPP5A) to inositol 1,4-
bisphosphate (Ins(1,4)P2) [15, 16]. ITPKA is the most
highly characterized ITPKs isoform, and found up-
regulated in lung cancer tumor tissues [11]. In the
present study, our data demonstrated that 48.9 % of
HCC patients showed elevated ITPKA expression in
their tumorous specimens compared with their normal
counterparts. However, down-regulation of ITPKA was
found in oral squamous cell carcinoma, suggesting that
ITPKA may serve as a tumor-suppressor [10]. Based on
these studies, the function of ITPKA seems to depend
on its cellular context.
We next investigated the clinicopathologic correlation
of ITPKA expression in HCC patients. The results
showed that overexpression of ITPKA correlated with
vascular invasion (P = 0.001) and TNM stage (P = 0.005),
which strongly suggested that ITPKA was involved in
the metastasis and progression of HCC. This is in an
agreement with two recent studies, which showed that
ectopic expression of ITPKA enhanced the metastatic
potential of tumor cells [11, 17]. Ca2+ is a ubiquitous
second messenger that mediates numerous cellular pro-
cesses, including cell proliferation, survival, apoptosis,
migration and gene expression. Increases of intracellular
Ca2+ concentration have long been known to be involved
in cell migration and invasion. Ins(1,4,5)P3 can bind to
the ER membrane Ca2+-permeable Ins(1,4,5)P3 receptor
(IP3R) channels, which results in the opening of the
membrane channel, and further release the stored Ca2+
into the cytosol [18, 19]. ITPKA metabolizes Ins(1,4,5)P3
to Ins(1,3,4,5)P4, which in turn terminates the signal to
release Ca2+ from the endoplasmic reticulum. On the
other hand, in some cases the Ins(1,3,4,5)P4, generated
by ITPKA, can protect Ins(1,4,5)P3 by competitively
inhibiting the activity of INPP5A and thus prolongs the
effect of Ins(1,4,5)P3 on Ca
2+ signals [20, 21]. Moreover,
a recent report demonstrated that in EGF-stimulated
tumor cells Ins(1,3,4,5)P4 prolonged Ca
2+ signaling by
activation of SOCE [17]. Hence, we speculated that
ITPKA might enhance the metastatic potential of HCC
cells by increasing intracellular Ca2+ concentration.
However, further studies are required to elucidate the
function and mechanisms of ITPKA that involved in the
Ca2+ signaling in HCC. During metastatic dissemination,
cancer cells must acquire the ability to migrate, which is
correlated with cytoskeletal remodeling. Independent of
its InsP3 kinase activity, ITPKA can modify spine shape
and internal microstructure by directly binding and
bundling actin filaments and/or by recruiting Rac1 and
associated signaling machinery [9, 22]. It has also been
shown that ITPKA induces the formation of filopodia-
and lamellipodia-like protrusions, and consequently en-
hances the migratory and invasive abilities of tumor cells
Table 2 Univariate Cox regression analyses for OS and RFS in HCCs
Clinical features OS RFS
HR (95 % CI) P value HR (95 % CI) P value
Age 0.678 (0.420–1.096) 0.113 0.653 (0.409–1.041) 0.073
Gender 2.297 (0.562–9.390) 0.247 2.526 (0.619–10.316) 0.197
HBsAg 3.379 (1.061–10.763) 0.039 3.581 (1.126–11.394) 0.031
AFP 2.187 (1.246–3.839) 0.006 2.000 (1.171–3.418) 0.011
Cirrhosis 1.025 (0.549–1.916) 0.937 1.127 (0.605–2.097) 0.707
Tumor size 2.161 (1.279–3.653) 0.004 1.870 (1.135–3.081) 0.014
Tumor number 2.475 (1.488–4.118) <0.001 2.576 (1.574–4.216) <0.001
Tumor encapsulation 0.674 (0.392–1.161) 0.155 0.722 (0.429–1.215) 0.221
Vascular invasion 6.074 (3.449–10.698) <0.001 5.722 (3.236–10.119) <0.001
Edmondson-Steiner 1.348 (0.832–2.186) 0.225 1.296 (0.810–2.074) 0.279
TNM stage 4.919 (3.014–8.082) <0.001 4.282 (2.654–6.907) <0.001
ITPKA expression 2.579 (1.567–4.245) <0.001 2.669 (1.638–4.349) <0.001
HR hazard ratio; CI confidence interval; statistical significance (P < 0.05) is shown in bold
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Fig. 2 Kaplan-Meier analysis of OS and RFS for ITPKA expression. a Kaplan-Meier analysis of OS and RFS for ITPKA expression in 135 cases of HCC
patients. b Stratified survival analysis according to the TNM stage. c Stratified survival analysis according to the serum AFP level
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[17, 23]. Consequently, the migration-promoting effect of
ITPKA is regulated by both enzyme activity-dependent and
activity-independent mechanism. Besides, Ins(1,3,4,5)P4 it-
self has the potential to regulate various cellular functions
by acting on multiple targets, the majority of which contain
pleckstrin homology (PH) domains [24]. One of earliest
suggested Ins(1,3,4,5)P4 effectors are channel proteins res-
iding in the plasma membrane. For example, Ins(1,3,4,5)P4
can activate K+ channels in the plasma membrane in co-
operation with the internal Ca2+ [25]. In mouse lacrimal ac-
inar cell, Ca2+-dependent Cl-channel is also implicated as a
Ins(1,3,4,5)P4 effector [26]. The second major class of
Ins(1,3,4,5)P4 effectors are regulators of the small G pro-
teins Ras and Rap. Ins(1,3,4,5)P4 plays contradicting
roles in different models: Ins (1,3,4,5) P4 promotes the
activation of a unique Ras-GAP (GAP1IP4BP), and con-
sequently inactivation of the Ras GTPase; or inhibits
RASA3 GAP activity by removing RASA3 from the
plasma membrane [27–29]. Nevertheless, until now, the
components of Ins(1,3,4,5)P4-based signaling systems are
far from clear. Further studies are required to define the
roles of ITPKA and its products precisely in HCC.
Our study also demonstrated that high expression of
ITPKA was one of the most important prognosis factors
for OS and RFS in the univariate and multivariate ana-
lysis. The 5-year RFS of patients with high ITPKA ex-
pression was markedly shorter than that with low
expression (26.8 % versus 57.7 %). It is known that HCC
patients with the same TNM stage, histopathologic fea-
tures of tumor, and treatment strategy (such as curative
resection) may experience quite different clinical out-
comes [30]. With the stratified survival analysis accord-
ing to the TNM stage, we found that the prognostic
significance of ITPKA still existed in subgroup of pa-
tients in early clinical stage (TNM stage I): the 5-year
RFS for ITPKA high expression and low expression pa-
tients was 40.0 % versus 72.1 % (P = 0.001). AFP is the
current gold standard and most commonly used bio-
marker for the diagnosis and monitoring the effective-
ness of treatment or recurrence in HCC patients [31].
Until now, there was no ideal biomarker for monitoring
recurrence and metastasis in HCC patients with normal
AFP level after curative resection [32, 33]. Interestingly,
we found that ITPKA status could stratified the normal
AFP level group into two subgroups with substantially
different 5-year RFS (29.3 and 74.2 % for ITPKA high
and low patients, respectively; P = 0.047). Given that
there were only 48 cases of HCC patients with normal
AFP level in the present study, further investigation with
a larger sample size is required to confirm this finding.
In conclusion, the results of present study for the first
time demonstrated that high expression of ITPKA in
HCC tumorous specimens indicated aggressive tumor
behaviors and predicted a poor clinical outcome. These
findings suggested that ITPKA may serve as a suitable
prognostic marker for HCC patients after surgery, espe-
cially in early clinical stage.
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